Hoth Therapeutics Inc (NASDAQ:HOTH) shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic showed cognitive improvements in an Alzheimer’s Disease (AD) mouse model.
Hoth Therapeutics says all of the behavioral tests performed after >5 weeks treatment showed a significant improvement in the HT-ALZ treated groups compared to the vehicle treated groups, with similar cognitive and behavioral trends in the HT-ALZ-treated groups compared to the wild type (non-AD) animals. Overall, Hoth Therapeutics says the results support the therapeutic potential of HT-ALZ to provide cognitive improvement as an AD therapeutic.
AD is a neurodegenerative disease that is characterized by aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease such as dementia.
See Also: Why Canoo Shares Shot Up Over 100% Today
Hoth Therapeutics is a development-stage biopharmaceutical company.
According to data from Benzinga Pro, Hoth Therapeutics has a 52-week high of $1.75 and a 52-week low of $0.38.
